MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study
Year: 2026
Type: conference-abstract
Authors: Meletios A Dimopoulos, Carolina Terragna, Niccola Bolli, Philippe Moreau, Paula Rodríguez-Otero, Mario Boccadoro, Joan Bladé, Niels WCJ van de Donk, Francesca Gay, Roberto Mina, Aurore Perrot, P Joy Ho, Annemiek Broijl, Meral Beksac, Mark van Duin, Diego Vieyra, Fredrik Borgsten, Melissa Rowe, Luca Bertamini, Pieter Sonneveld
Institutions: Korea University, National and Kapodistrian University of Athens, Istituto di Ematologia di Bologna, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Centre Hospitalier Universitaire de Nantes, Clinica Universidad de Navarra, Universidad de Navarra, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Turin, Emory University, Winship Cancer Institute, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Université de Toulouse, Royal Prince Alfred Hospital, Erasmus MC Cancer Institute, Istinye University, Liv Hospital, Johnson & Johnson (United States), Johnson & Johnson (United Kingdom)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204697017
Cites:
Cited by:
Related to: